Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
Recruiting in Palo Alto (17 mi)
+114 other locations
Age: Any Age
Sex:
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Boehringer Ingelheim
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
Research Team
BI
Boehringer Ingelheim
Principal Investigator
Boehringer Ingelheim
Eligibility Criteria
Treatment Details
Interventions
- Tipranavir (Protease Inhibitor)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
1182.70.010Joliet, IL
1182.70.044Portland, OR
1182.70.036New York, NY
1182.70.062New York, NY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Boehringer Ingelheim
Lead Sponsor
Trials
2566
Patients Recruited
16,150,000+